TILS.L Regulatory News (TILS)

16 Jul 2007 07:01

ReGen Therapeutics PLC16 July 2007 ReGen's Cognitive Nutraceutical Colostrinin (TM) Launched in Australasia ReGen Therapeutics Plc (London) have today announced that it has extended thescope of its licensing deal for Colostrinin(TM) with Metagenics Inc., its NorthAmerican licensee, by amendment to the License and Supply Agreement of 13 July2006. Colostrinin(TM) will be distributed in Australasia by Metagenicssubsidiary Health World Ltd - a leading supplier of natural medicines tohealthcare professionals, in these markets. The financial terms of this deal remain commercially confidential, although itcan be confirmed that all agreements with Metagenics involve the sale and supplyof the Colostrinin(TM) active ingredient to Metagenics for them to formulate,package and market. ReGen then receives a royalty out of the sale proceeds whenthe formulated product is sold. Percy Lomax, Executive Chairman of ReGen said: 'The launch of Colostrinin(TM) isa validation of the Company's work since 1998. It is the start of the Company'scommercial return from its research efforts'. Mike Curley, Chief Science Officer of Health World, added, 'We are very pleasedto be the first company in the world to launch Colostrinin. Based on theinterest shown in it by practitioners at the recent International Congress onNatural Medicine, we believe it will be an important breakthrough in helping tomaintain the cognitive health of the ageing population' Further information: Andrew MarshallGreycoat CommunicationsTel: 020 7960 6007Mobile: 07785 297111 Percy LomaxChairman and Chief ExecutiveReGen Therapeutics PlcTel: 020 7153 4920 Imran Ahmad/Cecil JordaanHB CorporateTel: 0207 510 8600 Notes to Editors About ReGen Therapeutics Plc ReGen Therapeutics is a UK listed Biotech company which is developing threebusiness lines - human and veterinary nutraceuticals, prescriptionpharmaceuticals for the treatment of neurodegenerative diseases and a clinicalresearch organisation which oversees Phase I and Phase II both for ReGen andexternal customers. ReGen's business strategy is to develop its nutraceuticaland pharmaceutical products to a state where they can be licensed out andmarketed by a third party. Its only direct sales are currently through itsclinical research organisation. www.regentherapeutics.com ReGen's shares are traded on the AIM Market of the London Stock Exchange plc(RGT) and are quoted on the Pink Sheets of the United States over-the-countermarket in the form of American Depositary Receipts (REGUY:PK). About Metagenics, Inc. Metagenics, Inc. is a leading developer, manufacturer and marketer ofscience-based nutraceuticals and medical foods sold to healthcare practitionersworldwide. The company is headquartered in San Clemente, California withmanufacturing and research facilities located in Gig Harbor, Washington-including its MetaProteomics(R) Nutrigenomics Research Center and its FunctionalMedicine Research Center(SM) for human clinical research. Metagenics holdsmultiple proprietary formula patents and produces over 400 research-basedproducts to optimize health. Metagenics demonstrates its commitment to purityand quality through its certifications for Good Manufacturing Practices (GMP)from the National Nutritional Foods Association, NSF International, and theTherapeutic Goods Administration of Australia. www.metagenics.com. About Health World Ltd. Health World Ltd is the leading supplier of natural medicine products tohealthcare professionals in Australasia. Founded in 1985, the company is basedin Brisbane Australia where it has a TGA approved GMP manufacturing facility.The company's mission to "Help people live happier healthy lives " is beingachieved through a commitment to providing quality products, superior educationand passionate service. This information is provided by RNS The company news service from the London Stock Exchange